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Objectives. We sought to investigate the hypothesis that estro- 
gen replacement therapy ameliorates symptoms in postmeno- 
pausal women with syndmmr X. 
Buckgmutid. Syndrome X (angina pectoris. positive findings on 
exercise electrocardiography and normal results on cnronaq 
angiopraphy) IrequenUy orcurs in menopausal women. This ob- 
semation, in conjunction with the known vasnactive properties of 
estrogens. suggests that estrogen depletion may contribute to the 
pathogenesis of syndrnme X in some women. 
Me/hods. Twenty-five postmenopausal pa!Ients with syndrome 
X completed a double-blind, placebo-controlled study of the elfect 
of ll-beta-estradiol cutaneous patches (100 a%24 h) on the 
frequency of chest pain and on exercise tolerance. Patients were 
Angina prctoris is usually associated with atheromatous coro- 
nay artery disease. but angiographically smooth coronary 
arteries arc found in 10% to 30% of patients undergoing 
coronary angiography to investigate angina1 chest pain (I-4). 
The triad of angina pectoris. an ischrmic-appearing exercise 
electrocardiogram (ECG) and angiographically smooth coro- 
nary arteries IS widely referred to as syndrome X (S). Although 
the prognosis of patients with syndrome X is excellent. they are 
frequently limited by chest pain in their daily activities. expe- 
ricncc considerable disruption to their quality of life and 
prcsenl continuing management problems (3.h). 
The pathophysiology of the troublesome chest pain in 
syndrome X is poorly understood. but there arc many sug- 
gested mechanisms (7-O). Syndrome X is likely to be a 
hcterogcncous condition: however. reduced coronary flon 
reserve induced by dipyridamole has heen rcportcd in some 
patients with this diagnosis (HJO). The majority of patients 
with syndrome X are women (4.11-13). of whom most arc 
postmenopausal (14) and have symptoms of ovarian failure. 
This observation. coupled with the evidente that estrogens 
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randomly assigned to receive either placebo or 17.beta-estradiol 
patches for 8 weeks and were then crossed over 10 the other 
treatment 
Results. During the placebo phase, patients had a mean of 7.3 
episodes of chest pain/IO days. A reduction to 3.7 episodes/IO days 
was observed during the I7-beta-estradiol phase (p < 0.05). No 
significant differences were observed b&ween the e&cts of 17. 
beta-estradiol and placebo on exercise duration or the resuhs of 
other cardiologic investigations. 
Conrhsions. Estrogen replacement reduces the h-equency of 
chest pain and may he a useful new therapeutic option for treating 
postmenopausal women with syndrome X. 
(I Am Cdl Cardid 1996;28:15(M-5) 
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have vasoactive properties (15-17). a deficiency of which is 
associated with vasomotor instahility (18). has led to the 
supgcstion that estrogen deficiency may play a central role in 
the pathogenesis of chest pain in postmenopausal patients with 
syndrome X. This hypothesis is supported by the finding that 
cutaneous vasodilator reserve. impaired in women with syn- 
drome X. is normalized by estrogen replacement therapy 
(13.19). 
The pl;rpose of this study was to examine the hypothesis 
that the chest pain in postmenopausal women with syndrome 
X would he lessened by estrogen replacement. thereby sug- 
gesting a role for estrogen deficiency in its pathogenesis. 
Because it remains unclear whether the chest pain in this 
condition is mediated by myocardial ischsmia. or hy another 
mechanism that produces both pain and ECG changes (20). 
exercise electrocardiography. thallium-201 perfusion scanning, 
and amhulato~ KG (Holtcr) monitoring ol’ ST segments wds 
:hlso performed. 
Methods 
Patients. Norinotensive’nondiatretic women ageb 40 to 65 
yea’rs with angina1 chest pain, ischemic-appearing exercise 
ECG (ST segment depression >I mm) and normal coronary 
arteriographic and echocardiographic findings were included 
in the study ‘if they had been amenorrhea1 for 26 months. with 
l)73s-Iw7,9fl/sls.lw) 
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a folllclc srimulating hormonrl (FSH) Ic~el grcatcr than 
JO IU!liter and rstradiol Icvel less than 1 IO pmol. liter. 
Trial design. Written informed consent was obtained from 
all patients, and cardiac drugs were stopped for the ZO-week 
duration of the trial. Only standard sublingual nitroglycerin 
was permitted as required. After a J-week run-in phase. 
patients were randomly assigned. in double-blind manner. to 
receive I7-beta-estradiol or placebo for 8 weeks: they then 
crossed uver tu the other treatment for X weeks (Fig. I ). The 
l7-beta-estradiol was administered in the form of self-adhcsi\,c 
cutaneous patches (Estraderm ‘lT!k Ciha Pharmaceuticals) 
providing a cutaneous absorption rate of 50 &3l h for weeks 
I, 2. 7 and 8 and I(10 rgI?J h for weeks 3 to 6 of the estrogen 
phase. The placebo patches were identical in appearance. and 
all patches were changed twice weekly. At the end of the 
second limb of the study protocol. patients received norethis- 
teronc acetate (NEA, 1 mglday orally) for 2 weeks (Fig. I). 
Patient assessment. Compliance was checked hy inkrview- 
ing the patients. inspecting all treatment patches after use and 
measuring estradiol levekduring each treatment period. All 
patients were asked to hcep a chest pain dia? throughout the 
study (every episode w;!s scored from I to 1 according to 
severity). Any other symptoms were also recorded hy the 
patient as indicatoc: :jf pos>‘hle adverse reactions. The diap 
data were analyzed dn the final IO-day periods of I) the run-in 
phase. 2) the l7-beta-estradiol l(HL~_ei”?J h phase. and 3) at the 
equivalent time during the placebo phase. At this time of 
evaluation of dia? data. steady state cstradiol plasma levels 
were predicted (21). At each of these time points, all patients 
undewent treadmill exercise testing and 48-h ambulatory 
ECG (Holter) ST segment monitoring. and undemcnt repeat 
exercise testing at the end of the NEA phase. Tomographic 
exercise thallium-201 scanning ~‘as performed at the end of 
kth the placebo and I7-beta-estradiol phases. 
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Exerizise testing. Sjai+ili-k.it:? L.\crci!,e testing was 
performrd by using the Bruce protocol. The ECG ,was evalu- 
ated by, using it cclml”rter-Hssistcd s\‘E!q:m (,Marquette CA>E 
12). X l2-lead ECG and blood pressure w!rc recorded at 
baseline. at the e?d of each esercise stage. at the onset of chest 
pain and at I-mm ST segment depression during esercisc. at 
peak rsercisc and during reco\ev. 
Ambulatoq ECG monitoring. Hblter morkoring was pcr- 
formed by using pregellrd electrodes to rcc,)rd two hipolar 
lcads (anterior lead CM, and a modified inferior lead). Two- 
channel recordings were made hy a frequency-modulated 
recorder (Oxford Medilog 7. Oxford. England. United King- 
dom). Tapes were analyzed hy experienced independent oh- 
servers using an Oxfcrd Medily MA20 scanner. and signifi- 
can! ST segment depression rb~ defined as planar or 
downsloping ST scgmcm shift >I ;rm measured 0.08 s after 
rhe .l point. with gradual onset and rcs.!&m lasting for ~60 s. 
Statistical analysis. The number of patients studied was 
specified in the original study design and kvas base4 cn the 
power of previously published studies (?I!.?3) to demonstrare 
significanr differences in rnd points similar to those in the 
present study. Rerl,lts were and!zed on an intention-to-treat 
basis. Where appropriate. an;:iyis of variance was performed. 
with treatment period. treatment sequencs and patient within 
sequence as factors. Nonparametric equivalent analysis hy the 
Koch approach (31) was performed when the data were not 
normally disttlouted or when previous knowledge of the nature 
of the data dictated. The results were uisl) analyzed on a pc‘r 
protocol hasis. Analyses were cunsidrrcd to show a significant 
Jiffercncc when p c: 0.05. 
Results 
Patients. Of 30 postmenopausal women with chest pain 
screened for Ihe trial. 26 were random!! assigned to initial 
treatment with I7-heta-estradiol or placeho. The principal 
reason for noninclusion in the study was a plasma estradiol 
level >I I(1 pmoi3iter. Of the 26 randomized patients. 12 
(a?) had had a hyste:ectomv before the Cnset of chest pain. 
One patient had previous&j heen treated with hormone ther- 
apy. The intcmal betHern hytctrcctomy (or last menstrual 
period) and the development of chest pain was 8.3 years (range 
-I to 17. n = I?). One patient discontinued treatment early in 
the crossover phase because of elevated Leer enzyme levels. 
and results of the remaining 25 wno completed the stud! to IX 
WC& (the end’ of 6 weeks of the crossover phase. before 
administration of NEA) were included in the statistical anal!- 
ses. The mean age of these 25 patients was 56.X years (range 37 
to 6.5). Four patients ‘wetc smokers. six had a family history 
of coronaF artetv disease and eight had a cholesterol level 
>6 m&l.‘liter. Fifteen of the 25 patients had menopausal 
symptoms consisting of night sweats and vaalmotrv mstahility 
During active treatment. plasma levels of I7-beta-estradiol 
were elevated to within tlie physiologic premenopausal range 
(386 2 223 pmol:liter). whereas plasma levels in the placebu 
phase were 53 2 51 pmol/liter. Despite having suitably low 
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Table 1. Eyrcisc Test Variables After 8 Weeks of Either Placeho 
or 17-Ijcta-Estradiol in 21 Patients* 
With WiIh 
PiXKho 17.Beta-Estradiol 
RC\l 
ilcarl rare (huts min) 762 11 ?7 f 13 
%od prcswrc (mm Hg) 127 z IS 13 T 11 
Exercise 
7’r: to cheu pain (s) 3s e !-II 341 L 162 
Time IO I-mm ST dcpro>ion (0 32 + 148 27s ?I I.53 
Ewcisc duration (3) 410 2 149 406 + 155 
Peak exerciw 
Heart rate (bcars’min) 141 -t 2: 141 2 I’ --
Blood pressure (mm Hg) 163 % 2.5 165 + -‘! 
‘llrrre WTK no significanl differences hchvecn values measured m the 
plawbo and ll-hefa-eslradiol phases. Data presented are mean value z SD. 
17-beta-estradiol levels during the run-in phase (~1 ;O pmol/ 
liter). two patients had levels >150 pmol/liter in the i,‘acebo 
phase. suggesting residual ovarian function. Four other pa- 
tients failed to have a significant increase in plasma 17-beta- 
estradiol levels in the drug phase. There was evidence that 
each of these patients had shown some deviation from the 
prescribed trial regimen during the study period, indicating 
that a degree of noncompliance may have been the cause of the 
low 17-beta-estradiol levels. 
Epiwdes of chest pain. The frequency of chest pain was 
significantly less with 17-beta-estradiol than with placebo (7.3 
vs. 3.7 mean number of episodes of chest pain/IO days; 95% 
confidence interval [Cl] -6.6 to 0, p < 0.05). 
Exercise testing. One patient was unable to exercise at the 
end of the 17-beta-estradiol phase because of severe back pain. 
In the remaining 24 patients no significant difference in 
exercise duration WG found between the 17-beta-estradiol and 
placebo phases (408 + 155 vs. 410 2 149 s), even after 
adjustment for crossover effects. Similar results were obtained 
from the per protocol analysis. All patients had :,I-mm ST 
segment depression on both 17-beta-estradiol and placebo 
exercise tests, but there was no significant difference in the 
times to this point, or in any other variable (Table 1). For each 
patient, the lead in which l-mm ST depression first occurred 
was the same for both treatment periods (lead II in 13 patients, 
lead III in 5 and lead V, to V, in 7). 
Of !he 24 patients who performed adequate exercise tests, 
14 had chest pain during either 17-beta-estradiol or placebo 
exercise tests, but only 4 were limited in their exercise toler- 
ance by chest pain alone in either or both tests. The time to 
onset of chest pain (or time to peak exercise in the abserice of 
chest pain) was similar in the two treatment phases (341 + 163 
vs. 354 2 141 s, ll-beta-estradiol vs. placebo, p = NS). 
Other cardiovascular investigations. Two patients had in- 
complete thallium-201 studies at one or both assessments. Of 
the remaining 23 patients, only 4 had perfusion defects in the, 
stress image in one of the two scans performed (2 while 
receiving placebo, 2 while receiving 17-betaestradiol). 
Of the 25 patients, 7 had ST segment changes during 48-h 
JACC Vd. 28. No. 6 
November IS, 199b:15lNl-5 
ambulaiov electrocardiography while receiving 17-l@ta- 
estradiol. and 8 while receiving placebo. Of thes’e episodes. 
60% were symptomatic. However, nonparametric analysis re- 
vealed a significant difference between the treatment se- 
quences, suggesting a cariyover effect of’ 17-beta-estiadiol 
when followed by placebo (p = 0.04). We therefore compared 
the first treatment period data for the two treatment groups by 
the Wilcoxon two-sample test, which showed a trend toward 
fewer episodes of ST segment changes with 17-beta-estradiol 
than with placebo (p = 0.39). 
Effects of NJ2A. We compared the results of assessment at 
18 weeks jocund-period treaiment alone) and at 20 weeks 
(after 2 weeks qf NEA administration with continuation of 
second-period treatment). One patient discontinued all study 
medication after 7 days of NEA because of worsening chest 
pain but was assessed at 20 weeks and included in the 
intention-to-treat analysis. 
There was no significant difference in the number of 
episodes of chest pain in the 10 days before assessments at 18 
and 20 weeks when placebo was the second-period treatment 
(6.69 2 5.56 vs. 6.69 2 5.96). When IFbeta-estradiol was the 
second-period treatment, the addition of NEA resulted in a 
trend toward an increased number of episodes (5.43 t 7.93 vs. 
10.77 f 11.91, p = 0.06). with a median increase of 1.9 
episodes (n = 12). There was no significant difference in 
exercise duration or time to l-mm ST segment depression for 
either second-period treatment. 
Subset analyses. Three of the four patients with low 17- 
beta-estradiol levels during the active treatment phase had no 
chest pain in the lo-day recording period of either treatment 
phase. Of the two patients with persistent ovarian function, 
neither had a reduction in the numhr of episodes of chebt pain 
with 17-beta-estradiol. Of the remaining subgroup of 19 
women with ovarian failure and a significant increase in plasma 
17-beta-estradiol levels during active treatment, 13 (68%) had 
fewer episodes of chest pain with 17-beta-estradiol than with 
placebo, and 2 patients reported no change; only 4 patients 
reported a greater frequency of chest pain with lFbeta- 
estradiol than with placebo. Subset analysis was performed in 
the 19 patients with inactive ovaries and adequate p!asma 
levels of 17-beta-estradiol during the 17-beta-estradiol phase. 
This subgroup had significantly fewer episodes of chest pain 
per IO-day period with 17-beta-estradiol than with placebo 
(-4.9 episodes. 95% Cl 0 to -9.2, p < 0.05) and had a greater 
benefit than the three patients with chest pain whose plasma 
17.beta-estradiol levels remained low during active treatment 
or who had evidence of ovarian functic.1 (+2.0 episodes). 
Analysis of the data for this subset of 19 patients,with inactive 
ovaries and adequate plasma levels of 17-beta-estradiol during 
active therapy did not show any significant differences with 
respect to all other measured variables. 
Adverse expcrktees. One patient had a serious adverse 
experience after 3 days of NEA administration (at the end of 
the placebo phase), with both marked exacerbation of chest 
pain and episodes of near fainting until all medications were 
stopped after 7 days of NEA treatment. fienty-three patients 
had minor adverse experiences during 17-beta-estradiol treat- 
ment, 21 during placeh) administration snd’lh during NE3 
administration. The most frequently rcportcd advcrsc cfkcts 
were hreast tenderness (with 17-Ma-estradiol only. n = 1.1). 
chest pain (with placebo onI>. n = 6) and dy\pnea. (with 
placebo. n = 5). With both 17-beta-estradiol and p!accho. two 
patients had skin redness at the site of patch application. 
Discussion 
This study demonstrates a significant reduction in the 
frequency of chest pain in estrogen-deficient women with 
syndrome X when treated with 17.beta-estradiol. supporting 
the hp)thesis that estrogen deficiency may play ;I role in the 
pathogcnesis of the symptoms in postmenopausal women with 
syndrome S. Despite this henrticial effect on chest pain. thcrc 
was no sienilicant change in exercise time or other test results. 
This apparent dissociation of chest pain frqrn ehercisc toler- 
ance and ST segment changes indicates that although syn- 
drome X is likely to he heterogeneous with multiple pathogc- 
netic components. the chest pain in most patients IS not due to 
myocardial ixhemia. 
Symptoms in patients with syndrome X. A variety of 
cardiac and noncardiac mechanisms for the symptoms in 
syndrome X have been proposed (12,2S-27). Among the 
cardiac mechanisms suggested as causing the chest pain. some 
investigators have invoked a disturbance of microvascular 
function as a central feature, and although myocardial isch- 
emia might he expected to be a common final mediator (8). this 
hypothesis is confounded hy the detection of ishemia in a 
highly variahlr and sometimes negligible proportion of these 
patients (18-34). Accordingly, the present results demonstrate 
a low incidence of thallium201 myocardial perfusion dcfccts 
(four defects in 24 patients). and the patients who responded 
to 17.beta-estradiol trcatmrnt were not identified hv any 
changes that might have been suggestive of ischcmia on 
exercise testing, thallium perfusion scanning or 48-h Halter 
monitoring in this study. Only I4 of the 2S study patients 
experienced worsening chest pain on baseline exercise testing. 
These lines of evidence. together with the repetitive and 
long-lasting nature of the chest pain in patients with syndrome 
X (7.14). sugest that the pain may not be mediated primarily 
by myocardial &hernia. thus explaining the apparent disslc’i- 
ation of chest pain from exercise tolerance. 
Prognosis in syndrome X. The inciden’ce of myocardial 
infarction and death in these patients is similar to if not lower 
than that of the general population (4). Despite this henign 
prognosis. the refractory nature of the chest pain, which 
interferes with daily activities, represents a significant problem 
for these pzitients. The principal aim of any therapeutic 
maneuvers must therefore be to relieve chest pain irrespective 
of any potential influences on myocardial ischemia or coronary 
blood flow. TherdpeUtk trials of standard antianginal therapies 
have proved disappointing in relieving chest pain in syndrome 
X. and therapeutic trials based on sJ$,ested nonischemic 
pathophysiologic mechanisms have recently heen undertaken 
(3). 
Estrogen and syndrome X. The clinicai ohsenfation that’ 
the majority of patients with syndrome X are women (4.1 l-13).’ 
of whom most are postmenopausal (36). Itid to the hypothesis: 
that cstrogcn deficiency may play a pathophysiologic role in at 
least ;I proportion cd patienls with syndrome,X (36). Estrogens 
have vasoactiuc properties (15.17.37-17). a deficiency of which 
is associated with vasomotor instability (43-45). We (10.36) 
have shown that ttstrogcn rrplacement therapy causes normal- 
ization of the impaired peripheral skin vasodilator reserve 
observed in women with syndrome X. The alleviation of chest 
pain hy l7-beta-estradiol ohserved in this study has several 
posslhlc explanations unrelated to myocardial ischemia. These 
include rclicf of the preartcriolar vasoconstricticm or augmcn- 
I;lIion of adcnosine-induced A, receptor-mediated vasodila- 
tion by a direct action on the casculsr smooth muscle cells 
(38.3Y). The net result of either of these actions would be 
expected to bc an increase in coronary flow with a reduced 
production of adc.losine. .Idenosine is a known algogen. 
excessive release of which or sensitivity to which. is sugested 
as hcing the painful stimulus in syndrome X. resulting in 
exa&&,crated cardiac sensitivity to nonischemic stimuli (both 
mechanical [Jh-481 and chemical. such as adenosine infusion 
[-IX]). The lessening of chest pain obscmed with l7-beta- 
estra:liol in the present study, in the absence of improvement 
in cardiac testing. therefore might result from attenuation of 
adenilsmc production or altcratilln 14 ih\; :i.dance or scnsiti3y 
of adcnosine receptors (MJY). Hcterogcneity of adcnosinc 
receptors or sensitivity may account for regional myocardial 
perfusion ahnormalities. ChnliilT vasodilulion by I7-beta- 
cstradid may idso relieve myocardial ischemia in the suhsct of 
patic‘nts in whom it is manifest. 
Possible analgesic mechanism of action of estrogen. The 
symptomatic benefits of 17-beta-estradiol in syndrome X may 
relate IO an analgesic action through other. as yet poorly 
understood. mechanisms. Another mechanism may involve 
analgesic properties of estrogen. Recent animal data (SO) have 
shown female-male differences in pain sensitivity. These dif- 
ferences were negated hi ovariectomy and rrestahlishcd after 
estrogen replacement. These data support the claim that 
cstmgcn has analgesic properties that ma! contribute to the 
results we ohserved. Recent observations hy Cannon ct al. (35) 
suggest that imipramine, known to have visceral analgesic 
properties. reduces chest pain without induring objective 
changes on formal cardiovascular testing, an effect similar to 
that of l7-beta-estradiol in the present study. Alternatively. 
there may he central effects on psycho!ogic instability. Psycho- 
somatic symptoms and panic disorders. (77) and a general 
reduction in pain threshold (12) have been associated with 
chest pain and possibly the ST segment changes in syndrome X 
(Sl). Thus. the effects of l’l-beta-cstrddiol in menopausal 
patients with syndrome X may be multifac!orial and may 
include an important improvement in the well-being of pa- 
ticnts that may increase the threshold to the perception of 
pain. 
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folcrancc in wt,men with +ndr,>mc S and udirncn with sttihlc angins 
peclorir. Am J Cardiol lYd7;N):.503-:. 
13. Gala\si AR. Kayki JC, Crra F. ct JI. Hear1 rate rqnmsc during cxcrcisr: 
tckting .md amhulatq ECG moniloring in pat&t* with +yndromr X. .-\m 
llrart J IWI:I”:4SEI-6.3. “” 
14. l&ki JC. Rl,sanr, GMC. Collint P. Siho~annopouh~~ P. Mgrri A. Poole- 
timikion of the study. One iimitatiori of this stud;< KIS 
the inclusion of two patients with’r&idual ovarian. fur,c:,ion. 
dqspitr horn&e levels satistjing the inclusion crite!ia ;II the 
time-of screening. and of four patients who failed to show .I rise 
in plasma e~tradioi levels while receiving actijc therapy. ‘The 
ION plasma lei,els of 17-beta-estradiol during, active theI spy 
may have resulted from noncompliance. but failure of cut; nc- 
ous absorption of the drug is a possible alternative explanat cln. 
E6ert of added progestogen. The addition of NElA to 
17-beta-estradiol therapy (but not placebo administration) 
produced a marginally nonsignificant incrsasc in the number of 
episodes of chest pain, and in one patient introduction of NEA 
resulted in worsening of chest pain to the point of althdra~al 
from the trial. Progcstogens antagonize some of the actions of 
estrl gens. e.;pecially in the uterine circulation (5253). and 
their use may counteract the benefit of 17-beta-estradiol or 
cvcn cause a rebound exacerbatron of chest pain: however. this 
possibility requires further investigation. 
Treatment of qyndrome X with estrogen. The symptomatic 
benefit derived from 17.beta-estradiol therapy in the present 
study demonstrates that 17-beta-estradiol Jeficicncy is a likely 
caur;e of the worsening of symptoms in patients with syndrome 
X after menopause. 17-Beta-estradiol replacement therapy 
may be a useful new treatment of postmenopausal women with 
chest pain and normal coronary angiograms *ho continue to 
have troublesome symptoms despite reassurance of a good 
prognosis. 
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